We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Mesa Biotech Showcases PCR Testing Platform at Clinical Expo

By LabMedica International staff writers
Posted on 02 Aug 2018
Print article
Image: The Accula Dock system (Photo courtesy of Mesa Biotech).
Image: The Accula Dock system (Photo courtesy of Mesa Biotech).
Mesa Biotech Inc. (San Diego, CA, USA), a privately-held, molecular diagnostic company, showcased its affordable PCR (polymerase chain reaction) testing platform designed specifically for point-of-care (POC) infectious disease diagnosis at the 70th Annual American Association of Clinical Chemistry Scientific Meeting & Clinical Lab Expo (AACC). AACC 2018 was held on July 29 – August 2, 2018, in Chicago, Illinois, USA.

Mesa Biotech designs, develops, manufactures and commercializes next generation molecular diagnostic tests, bringing the superior diagnostic performance of nucleic acid PCR amplification to the POC. At AACC 2018, Mesa Biotech showcased its novel Accula System – a palm-sized, reusable dock with disposable test cassettes that offers the simplicity, convenience and procedural familiarity of traditional POC rapid immunoassays, while providing the superior sensitivity, specificity and information content of laboratory-based PCR testing. Test results are available in approximately 30 minutes to guide same-day treatment decisions. The handheld platform delivers flexibility in POC, ranging from the physician's office and walk-in clinics to emergency rooms. Accula Flu A/Flu B, the first commercialized test on the platform, is indicated for use with nasal swab collection that is less invasive than nasopharyngeal swabs and allows for a more comfortable specimen collection experience for the patient.

"We are excited to be a part of this leading industry conference and showcase our recently launched testing platform to the more than 20,000 attendees," said Hong Cai, Co-founder and Chief Executive Officer, Mesa Biotech, Inc. "AACC is an important opportunity for us to connect with global leaders, highlight new assays under development and identify additional partnership opportunities."

Related Links:
Mesa Biotech


Print article

Channels

Molecular Diagnostics

view channel
Image: Summary of changes FKBPL and CD44 changes throughout gestation in pregnancies complicated by pre-eclampsia (Photo courtesy of Oxford Press)

Elevated Levels of Two Protein Biomarkers Indicate Potential for Development of Pre-Eclampsia

A pair of novel protein biomarkers has been identified in the blood of asymptomatic pregnant women that can be used to predict the potential onset of pre-eclampsia. Pre-eclampsia (PE) is a disorder... Read more

Pathology

view channel
Image: The Idylla system is a fully-automated, real-time polymerase chain reaction (PCR) based molecular testing system designed to offer results in a minimal amount of time (Photo courtesy of Biocartis).

Rapid Genomic Profiling of Colon Cancers Improves Therapy Selection

Colorectal cancer is a malignant tumor arising from the inner wall of the large intestine (colon) or rectum. Colorectal cancer is the third leading cause of cancer in both men and women in the USA.... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.